A modified TB vaccine could treat bladder cancer
An animal study has shown that a modified vaccine for tuberculosis could treat bladder cancer whilst minimising side effects.
List view / Grid view
An animal study has shown that a modified vaccine for tuberculosis could treat bladder cancer whilst minimising side effects.
A new study in mice has shown blood cancer treatment with protein interleukin-7 revs up T-cell immunotherapy.
Looking at disease through a patient’s memory B cells can reveal vulnerabilities within pathogens. In this article, Dr Purnanand Sarma, President and Chief Executive Officer of Immunome, explores how advancements in memory B-cell antibody-based treatments will improve our understanding of how these cells can aid in fighting cancer and other diseases.
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…
Included in this ebook are articles on how to develop more effective CAR T cells by modifying the CAR design and why recent findings about ferroptosis in cancer cells could enhance immunotherapies.
Scientists have developed a genetic screening platform to identify genes that can enhance immune cells to make them more persistent and increase their ability to eradicate tumour cells.
Researchers have developed a pH-sensitive drug delivery system in T cells using C-terminal dendrimers with Phenylalanine.
Pre-clinical research has found that CAR T cells can suppress gastrointestinal cancer cells without causing harm to healthy tissues.
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
Research in mice has shown that adding anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumour growth.
Scientists have discovered a new strategy that can make pancreatic tumours visible to the immune systems of mice and vulnerable to immune attack.
Scientists have created a pipeline for identifying, prioritising and evaluating potential tumour antigens for personalised cancer vaccines.
Scientists have discovered the essential role of a ligand-dependent corepressor to potentially enable cancer cells to present tumour antigens on their surfaces.
New research has discovered metabolic mechanisms that contribute to how ovarian cancer escapes from immune attack and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
A new study has highlighted an enzyme called ART1 as a promising target for immunity-boosting cancer treatments.